2017
DOI: 10.1016/j.jacl.2017.03.001
|View full text |Cite
|
Sign up to set email alerts
|

Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
24
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 41 publications
(25 citation statements)
references
References 25 publications
1
24
0
Order By: Relevance
“…We previously defined PCSK9 inhibitor-induced discordance as expected LDL-C reduction without significant Lp(a) reduction (LDL-C reduction >35% and Lp(a) reduction 10%), and recently published an analysis of four Phase 3 clinical trials to determine the prevalence of discordance with evolocumab therapy. 22,23 Overall, the prevalence of expected LDL-C reduction in the absence of significant Lp(a) reduction (discordance) after evolocumab therapy was 18.4%. Furthermore, the prevalence of discordance was influenced by baseline Lp(a), being more common in patients with higher baseline Lp(a).…”
Section: Introductionmentioning
confidence: 98%
See 2 more Smart Citations
“…We previously defined PCSK9 inhibitor-induced discordance as expected LDL-C reduction without significant Lp(a) reduction (LDL-C reduction >35% and Lp(a) reduction 10%), and recently published an analysis of four Phase 3 clinical trials to determine the prevalence of discordance with evolocumab therapy. 22,23 Overall, the prevalence of expected LDL-C reduction in the absence of significant Lp(a) reduction (discordance) after evolocumab therapy was 18.4%. Furthermore, the prevalence of discordance was influenced by baseline Lp(a), being more common in patients with higher baseline Lp(a).…”
Section: Introductionmentioning
confidence: 98%
“…Though Lp(a) may be cleared partly through the LDLR, several lines of evidence point toward alternative mechanisms. [22][23][24][25] If Lp(a) clearance was fully accounted for by the LDLR pathway, one would anticipate PCSK9 inhibitor therapy to consistently reduce LDL-C and Lp(a) in a 2:1 ratio (a concordant reduction) in the same individual. We previously defined PCSK9 inhibitor-induced discordance as expected LDL-C reduction without significant Lp(a) reduction (LDL-C reduction >35% and Lp(a) reduction 10%), and recently published an analysis of four Phase 3 clinical trials to determine the prevalence of discordance with evolocumab therapy.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The association of PCSK9 with LDL particles lowers the ability of PCSK9 to bind to cell surface LDLRs thereby blunting PCSK9-mediated LDLR degradation [8]. In addition, PCSK9 also binds to Lp(a) [9], an effect that could partially explain the reduction of plasma Lp(a) levels observed in hypercholesterolemic patients treated with monoclonal antibodies against PCSK9 [10,11], for which the molecular mechanism is still unknown, although pathways beyond the LDLR appears to be involved [12]. More controversial is the binding of PCSK9 to HDL [13].…”
Section: Introductionmentioning
confidence: 99%
“…© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy Ther Apher Dial, Vol. 23, No 4,. 2019 Letters to the Editor…”
mentioning
confidence: 99%